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SHORT COMMUNICATION
A comparison of four new antiepileptic medications
THERESA L. COLLINS, OGNEN A. C. PETROFF & RICHARD H. MATTSON
Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA
In order to select a new medication for a patient with epilepsy, it would be helpful to have an idea of which drug might have
the greatest overall chance for success. Since epilepsy is a chronic disorder, the long-term effectiveness and tolerability of the
medications are very important. Here, we compared gabapentin, lamotrigine, topiramate and vigabatrin using Kaplan–Meier
survival analysis to see how long patients chose to stay on each drug and if they stopped, why they stopped. The results seem
to suggest the type of responses to be expected in a hospital seizure clinic.
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INTRODUCTION
For complex partial seizures, several new drugs have
become available in recent years. Each has its own
mechanisms of action, benefits and side effects. With
this in mind, a clinician must decide which to try
first. One measure of a medication’s success may be
whether patients stay on it or not. This was a pri-
mary outcome used by Mattson et al.1 in the two VA
Cooperative studies comparing valproate to standard
antiepileptic drugs (AEDs), in which duration of par-
ticipation in the trial was considered a measure of the
drugs’ overall success in terms of efficacy and tolera-
ble adverse effects.
While many studies have been done on each individ-
ual new AED as add-on therapy, few compare these
relative newcomers with each other. Marson et al.2
have performed meta-analyses comparing randomized
placebo-controlled add-on trials of new AEDs in pa-
tients with partial epilepsy. They have provided an es-
timate of each drug’s efficacy and tolerability com-
pared with a placebo and then compared these esti-
mates across drugs. Most recently, Wong et al.3 anal-
ysed the long-term use of gabapentin (GBP), lamot-
rigine (LTG) and vigabatrin (VGB) in patients with
chronic, primarily generalized and complex partial
epilepsy. They used Kaplan–Meier survival analysis
and Cox regression for comparison as well as using
efficacy and incidence of side effects. Here, we look
at the longevity of treatment in patients with complex
partial epilepsy on GBP, LTG, topiramate (TOP) and
VGB. These drugs were compared with each other us-
ing Kaplan–Meier survival analysis and, if they were
discontinued, the reason was noted.
METHODS
A retrospective chart review was conducted to include
61 refractory complex partial epilepsy patients from
our current clinics who were on GBP, LTG, TOP or
VGB. In most cases (83%) this included patients who
had tried more than one new AED. These 61 subjects
contributed 126 cases of new AED use. It was a prag-
matic look at data from patients who were in open-
label studies as well as on a marketed drug. We were
looking to approximate the response one might be able
to predict.
Sixty-four percent of the subjects were female with
36% male. They ranged in age from 20 to 84 years,
with the majority between the ages of 30 and 50 years
(mean age 43 years). Patients who had had surgery
were not included. All patients were experiencing re-
fractory complex partial seizures (ranging from 1 to
20 partial seizures per month) at the time a new AED
was added. All medications were taken to the maxi-
mum tolerated dose if complete seizure control was
not achieved. All were on at least one other seizure
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Fig. 1: Nonparametric survival plot for Gabapentin–Vigabatrin. Kaplan–Meier method, censoring column in C2–C8. ——,
Gabopentin; – – –, lamotrigine; - - - -, topiramate; – · –, vigabatrin.
Table 1:
Results
Gabapentin Lamotrigine Topiramate Vigabatrin
Number of patients 36 37 28 26
Time to 50% drop-out 13 >43 9.5 29
(median duration in months)
Percentages discontinued 21 (58%) 9 (24%) 7 (25%) 16 (62%)
due to lack of efficacy
Percentages discontinued 8 (22%) 6 (16%) 7 (25%) 3 (12%)
due to side effects
Continuing 7 (19%) 22 (60%) 14 (50%) 7 (27%)
medication prior to starting their new AED. All sub-
jects were under the care of the same physician in
the same location. Almost all had onset of epilepsy in
childhood.
We looked at the length of time patients used each
medication and the primary reason for discontinua-
tion, if they did not continue new AED therapy. A sur-
vival analysis was performed for each drug using the
Kaplan–Meier method. Time to failure was the vari-
able and patient data were censored if continuing on
therapy at the time of data collection (Fig. 1).
The most common side effect of TOP was severe
irritability, which occurred in seven out of ten discon-
tinuations due to side effects. The side effects reported
for all drugs included the usual CNS symptoms which
are commonly associated with the established AEDs,
for example: dizziness, tiredness, difficulty thinking,
weight gain and occasional rash (two GBP and three
LTG). Loss of efficacy over time was as common with
VGB as lack of efficacy from the outset; this was in-
cluded as half of the discontinuations due to lack of
efficacy.
RESULTS
See Table 1.
DISCUSSION
Although these numbers are small, the data do sug-
gest some information. Lamotrigine appeared to be
least likely to be discontinued by a rather wide mar-
gin. Its low rate of side effect discontinuation and
strong efficacy combine to make it the drug that more
patients have taken the longest in our clinic. Top-
iramate seemed equally efficacious, with the most
dropouts out of all the drugs due to side effects. And,
while GBP and VGB appear equally matched with
each other for efficacy, VGB had the fewest side ef-
fects determining drop-out of all the new drugs.
Recently, Wong et al.3 have suggested that patients
with both primary and complex partial epilepsy were
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less likely to stop LTG therapy than GBP or VGB. In
the past, Marson et al.4 have concluded in their meta-
analysis that LTG seemed least likely to be discontin-
ued. McDonnell and Morrow5 in their audit of GBP,
LTG and VGB showed similar results for these drugs.
They also saw evidence of tolerance with VGB.
Crawford6 has found the incidence of psychiatric
symptoms significantly higher in patients taking TOP,
and an overall dropout due to side effects (41%) which
was significantly higher than ours. But incidence of
these adverse effects could be reduced by using 25 mg
dose increments. Our patients had been titrated slowly
for TOP and all of the other drugs except VGB, which
we had been able to start immediately at a maintenance
dose (3 g) without any problem in many patients.
In general, our findings support those of other re-
searchers in hospital clinic settings.
REFERENCES
1. Mattson, R. H., Cramer, J. A. and Collins, J. F. et al. A compar-
ison of valproate with carbamazepine for the treatment of com-
plex partial seizures and secondarily generalized tonic–clonic
seizures in adults. New England Journal of Medicine 1992; 327:
765–771.
2. Marson, A. G., Kadir, Z. A., Hutton, J. L. and Chadwick, D. W.
The new antiepileptic drugs: A systematic review of their effi-
cacy and tolerability. Epilepsia 1997; 38 (8): 859–880.
3. Wong, I. C. K., Chadwick, D. W., Ferwick, P. B. C., Mawer, G.
E. and Sander, J. W. A. S. The long-term use of gabapentin, lamo
trigine and vigabatrin in patients with chronic epilepsy. Epilep-
sia 1999; 40 (10): 1439–1445.
4. Marson, A. G., Kadir, Z. A., Hutton, J. L. and Chadwick, D. W.
The new antiepileptic drugs. A systematic review of their effi-
cacy and tolerability. Epilepsia 1997; 38 (8): 859–880.
5. McDonnell, G. V. and Morrow, J. I. An audit of the new
antiepileptic drugs in clinical neurological practice. Seizure
1996; 5 (2): 127–130.
6. Crawford, P. An audit of topiramate used in a general neurology
clinic. Seizure 1998; 7 (3): 207–211.
